` 000963 (Huadong Medicine Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

000963
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -9% compared to the Shanghai Composite's 10% growth.

Stocks Performance
000963 vs Shanghai Composite

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
000963 vs Shanghai Composite

Loading
000963
Shanghai Composite
Difference

Performance By Year
000963 vs Shanghai Composite

Loading
000963
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Huadong Medicine Co Ltd vs Peers

Shanghai Composite
000963
MCK
COR
0HF3
CAH
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Huadong Medicine Co Ltd
Glance View

Market Cap
57.5B CNY
Industry
Health Care

Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.

Intrinsic Value
56.24 CNY
Undervaluation 42%
Intrinsic Value
Price
Back to Top